<div id="readability-page-1"><ul><li>MarketBeat’s Top 5 Rated Small-Cap Stocks</li></ul><p>Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) - Equities researchers at HC Wainwright decreased their FY2030 earnings estimates for Trevi Therapeutics in a research report issued to clients and investors on Wednesday, May 6th. HC Wainwright analyst B. Folkes now forecasts that the company will post earnings of $0.70 per share for the year, down from their prior forecast of $0.79. HC Wainwright currently has a &#34;Buy&#34; rating and a $21.00 target price on the stock. The consensus estimate for Trevi Therapeutics' current full-year earnings is ($0.46) per share.</p><div><p><span></span><span>Get <strong>Trevi Therapeutics</strong> alerts:</span></p></div><p>Other equities analysts also recently issued reports about the company. Morgan Stanley  restated an &#34;overweight&#34; rating and issued a $20.00 price target on shares of Trevi Therapeutics in a research note on Wednesday. Weiss Ratings  restated a &#34;sell (d-)&#34; rating on shares of Trevi Therapeutics in a research note on Monday, April 20th. Needham &amp; Company LLC dropped their price target on Trevi Therapeutics from $24.00 to $23.00 and set a &#34;buy&#34; rating on the stock in a research note on Wednesday. JonesTrading dropped their price target on Trevi Therapeutics from $25.00 to $24.00 and set a &#34;buy&#34; rating on the stock in a research note on Thursday, March 19th. Finally, D. Boral Capital  restated a &#34;buy&#34; rating and issued a $19.00 price target on shares of Trevi Therapeutics in a research note on Friday, April 17th. Two analysts have rated the stock with a Strong Buy rating, nine have issued  a Buy rating and one  has issued  a Sell rating to the stock. According to data from MarketBeat.com, the stock  has a consensus rating of &#34;Buy&#34; and a consensus target price of $21.70.</p><p><b>Check Out Our Latest Stock Report on Trevi Therapeutics</b></p><h2>Trevi Therapeutics Stock Down 2.7%</h2><p>Shares of TRVI stock opened at $14.26 on Thursday. The company has a 50 day moving average price of $12.63 and a 200-day moving average price of $11.92. The firm has a market capitalization of $1.83 billion, a PE ratio of -44.56 and a beta of 1.07. Trevi Therapeutics has a 52 week low of $5.38 and a 52 week high of $16.12. </p><p>Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) last announced its quarterly earnings results on Tuesday, May 5th. The company reported ($0.09) EPS for the quarter, missing analysts' consensus estimates of ($0.07) by ($0.02). </p><h2>Hedge Funds Weigh In On Trevi Therapeutics</h2><p>A number of institutional investors have recently bought and sold shares of the stock. China Universal Asset Management Co. Ltd. raised its holdings in  Trevi Therapeutics by 4.5% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 21,346 shares of the company's stock worth $195,000 after purchasing an additional 911 shares during the period.  Hilton Head Capital Partners LLC raised its holdings in  Trevi Therapeutics by 32.6% in the 1st quarter. Hilton Head Capital Partners LLC now owns 4,250 shares of the company's stock worth $51,000 after purchasing an additional 1,044 shares during the period.  Ameritas Investment Partners Inc. raised its holdings in  Trevi Therapeutics by 20.5% in the 3rd quarter. Ameritas Investment Partners Inc. now owns 7,632 shares of the company's stock worth $70,000 after purchasing an additional 1,300 shares during the period.  Kennedy Capital Management LLC raised its holdings in  Trevi Therapeutics by 2.4% during the fourth quarter. Kennedy Capital Management LLC now owns 56,269 shares of the company's stock valued at $704,000 after acquiring an additional 1,336 shares during the period.  Finally, Mirae Asset Global Investments Co. Ltd. raised its holdings in  Trevi Therapeutics by 32.3% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,231 shares of the company's stock valued at $78,000 after acquiring an additional 1,523 shares during the period. 95.76% of the stock is owned by institutional investors. </p><h2>About Trevi Therapeutics</h2> (Get Free Report)<p>Trevi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel non-opioid therapies for the management of chronic and acute pain. The company leverages proprietary drug delivery platforms and targeted molecular approaches to address high unmet needs in cancer-related pain, chemotherapy-induced neuropathy and other severe pain conditions.  </p><p>Its lead product candidate is a proprietary formulation of tetrodotoxin (TTX), a sodium-channel blocking agent being evaluated in early-stage clinical trials for moderate-to-severe pain associated with advanced cancer and peripheral neuropathy.</p><h2>See Also</h2><ul><li>Five stocks we like better than Trevi Therapeutics</li></ul> <p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VFJWSQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VFJWSQ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Trevi Therapeutics Right Now?</h2><p>Before you consider Trevi Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Trevi Therapeutics wasn't on the list.</p><p>While Trevi Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

TRVI

LABU

PILL

<p>Equities researchers at HC Wainwright have lowered their FY2030 earnings estimates for Trevi Therapeutics (NASDAQ:TRVI) from $0.79 to $0.70 per share. The firm maintains a "Buy" rating with a target price of $21.00. Other analysts have varied opinions, with Morgan Stanley and Needham & Company also issuing buy ratings but with different price targets. Trevi's stock has seen a recent decline of 2.7%, opening at $14.26, and has a market cap of $1.83 billion. The company focuses on developing non-opioid therapies for pain management.</p>

Market Beat

Trevi Therapeutics

VG Health

Direxion S&P Biotech Bull 3X

Invesco Dorsey Wright Healthcare Momentum ETF

VanEck Biotech ETF

iShares Biotechnology ETF

SPDR S&P Biotech

iShares US Pharma

Direxion Pharma & Medical Bull 3X

Health Care Select Sector SPDR

Morgan Stanley

Alliance HC

REPUBLIC HC

Hancock Whitney

Nano Labs

Weis Markets

Carl Zeiss Meditec AG

NEUBERGER BERMAN REAL ES-W/I

Landbridge Co LLC

Chemours

New England Real Asso

Jewett-Cameron

TJGC

D. BORAL ARC ACQUISITION I CORP. C/WTS 23/07/2030(TO PUR COM)

D Boral ARC Acquisition I

D Boral ARC Acquisition I - Unit

CHINA EB LTD

Arcadian Asset

SC ASSETS HLDGS - D

Rit Capital Partners PLC

Hennessy Capital Investment Corp VII

Hennessy Capital Investment Corp VII - Unit

Virtus Investment

Artisan Partners Asset Management 

VGI Partners Global Investments Ltd.

Kennedy-Wilson

Annaly Capital Mgmt

Sun Capital Management Corp.

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

Hancock Whitney Pref Share HWCPZ 6.25 06/15/60

China Everbright Water

EB GRAND CHINA

ANNALY CAPITAL MANAGEMENT INC 6.95% FXD FLTG CUM RED PFD SR F 30/09/22

ANNALY CAPITAL MANAGEMENT INC 8.875 CUM PREF SER J

ANNALY CAPITAL MANAGEMENT INC 6.750% FXD TO FTG RATE CUM RED PRF SR I

ANNALY CAPITAL MANAGEMENT INC 6.50 CUM RED PFD STK FIX FLT SER G USD25

Research Analysts Set Expectations for TRVI FY2030 Earnings